Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 3:18 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 2,486 matching trials from the live ClinicalTrials.gov search.
Conditions
Advanced Breast Cancer, Advanced or Metastatic Breast Cancer, Metastatic Breast Cancer (HR+/ HER2-), Metastatic Colorectal Adenocarcinoma
Interventions
PF-08165784, Fulvestrant, Atirmociclib, Cetuximab, Letrozole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
268 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
4
States / cities
Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 1 more
Conditions
Advanced Solid Tumor
Interventions
LM-302
Drug
Lead sponsor
Turning Point Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
7
States / cities
Duarte, California • Fullerton, California • Lafayette, Indiana + 4 more
Conditions
Ewing Sarcoma, Colorectal Adenocarcinoma
Interventions
INBRX-109, Irinotecan, Temozolomide, carboplatin, pemetrexed, Leucovorin, Fluorouracil, Bevacizumab, Trifluridine + Tipiracil
Drug
Lead sponsor
Inhibrx Biosciences, Inc
Industry
Eligibility
12 Years to 85 Years
Enrollment
411 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
24
States / cities
Scottsdale, Arizona • Beverly Hills, California • Duarte, California + 20 more
Conditions
Advanced Solid Tumors, Metastatic Triple Negative Breast Cancer
Interventions
NK012 and carboplatin
Drug
Lead sponsor
Nippon Kayaku Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Advanced Malignancies, Solid Tumor, Hematological Malignancy
Interventions
Pelabresib
Drug
Lead sponsor
Constellation Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
3
States / cities
Canton, Ohio • Gettysburg, Pennsylvania • West Valley City, Utah
Conditions
Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
bortezomib
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
5
States / cities
Boston, Massachusetts • New York, New York
Conditions
In Escalation: All Patients With Solid Tumors and Lymphoma, In Expansion: Melanoma, Non-small Cell Lung Cancer
Interventions
NIZ985, Spartalizumab, Tislelizumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Duarte, California • La Jolla, California
Conditions
Advanced Solid Tumors, Lymphomas
Interventions
Camptothecin-20-O-Propionate Hydrate (CZ48)
Drug
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
2
States / cities
Albuquerque, New Mexico • San Antonio, Texas
Conditions
Advanced or Metastatic Solid Tumors
Interventions
DCBY02
Drug
Lead sponsor
DynamiCure Biotechnology
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
3
States / cities
Scottsdale, Arizona • Aurora, Colorado • Boston, Massachusetts
Conditions
Solid Tumors, Multiple Myeloma, Non-Hodgkins Lymphoma, Pancreatic Neuroendocrine Tumors, PNET, NHL
Interventions
DCR-MYC
Drug
Lead sponsor
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
6
States / cities
Stanford, California • Chicago, Illinois • Boston, Massachusetts + 3 more
Conditions
Solid Tumors Harboring NTRK Fusion
Interventions
Larotrectinib (Vitrakvi, BAY2757556)
Drug
Lead sponsor
Bayer
Industry
Eligibility
Up to 21 Years
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
11
States / cities
Los Angeles, California • Palo Alto, California • Orlando, Florida + 7 more
Conditions
Advanced Solid Tumors, Triple Negative Breast Cancer
Interventions
TT-00420
Drug
Lead sponsor
TransThera Sciences (Nanjing), Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Houston, Texas
Conditions
Advanced Solid Tumor
Interventions
M0324, Pembrolizumab, mFOLFIRINOX
Biological · Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
3
States / cities
New Haven, Connecticut • New York, New York • San Antonio, Texas
Conditions
Advanced Solid Tumors
Interventions
ADCT-901
Drug
Lead sponsor
ADC Therapeutics S.A.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
7
States / cities
Denver, Colorado • New Haven, Connecticut • Atlanta, Georgia + 4 more
Conditions
NSCLC, HNSCC, Melanoma, Metastatic Cancer, Advanced Solid Tumor, Advanced Cancer
Interventions
CJRB-101, Pembrolizumab injection
Drug
Lead sponsor
CJ Bioscience, Inc.
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Irvine, California • Pittsburgh, Pennsylvania
Conditions
Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Any Solid Tumor
Interventions
LOXO-292
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
12 Years and older
Enrollment
857 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
41
States / cities
Scottsdale, Arizona • Duarte, California • Los Angeles, California + 33 more
Conditions
Advanced Solid Tumors
Interventions
Venetoclax, Rovalpituzumab Tesirine, ABBV-181
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
5
States / cities
La Jolla, California • Chicago, Illinois • Huntersville, North Carolina + 2 more
Conditions
Advanced EGFR Mutant Non Small Cell LungCancer (NSCLC), KRAS G12-mutant NSCLC, Esophageal Squamous Cell Cancer (SCC), Head/Neck SCC, Melanoma, Advanced Gastrointestinal Stromal Tumors (GIST), Advanced NRAS/BRAFT wt Cutaneous Melanoma
Interventions
TNO155, TNO155 in combination with EGF816 (nazartinib)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 99 Years
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
4
States / cities
Tampa, Florida • Boston, Massachusetts • New York, New York + 1 more
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
cisplatin, fenretinide, paclitaxel
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Advanced Solid Tumors, Multiple Myeloma
Interventions
ONC-201
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
bevacizumab, erlotinib hydrochloride, everolimus
Biological · Drug
Lead sponsor
Herbert Hurwitz, MD
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Colorectal Neoplasms
Interventions
5-fluorouracil
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Advanced Solid Tumor, Cutaneous T-cell Lymphoma (CTCL)
Interventions
SIM1811-03
Drug
Lead sponsor
Jiangsu Simcere Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
6
States / cities
Detroit, Michigan • New York, New York • Huntersville, North Carolina + 2 more
Conditions
Solid Tumor, Relapsed Solid Neoplasm, Refractory Tumor
Interventions
STI-6643
Biological
Lead sponsor
Sorrento Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
5
States / cities
San Diego, California • Sioux Falls, South Dakota • Austin, Texas + 2 more